$CC

Chemours Co (CC): Results of Operations and Financial Condition

Chemours Co (CC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cc-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 The Chemours Company Reports Second Quarter Results Wilmington, Del., August 4, 2026 – The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Thermal & Special

Original reporting
Published Aug 4, 2026, 8:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$CC
Neutral
medium confidence
Mentioned
$CC
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CCNeutralMed
01

Why it matters

Traders can reassess valuation drivers around cash generation, leverage trajectory, and segment-level volume versus pricing, while monitoring how litigation-related reserves affect GAAP losses versus non-GAAP metrics.

02

Market read

Fresh quarterly numbers show net loss narrowing versus prior year, adjusted EBITDA near the prior-year level, and a sharp improvement in free cash flow and leverage, alongside ongoing volume softness in refrigerants.

03

What to watch

Volume headwinds in TSS Opteon blends and the Washington Works outage cost in APM could dominate the narrative even with pricing increases and leverage improvement.

Relevance 7/10Novelty 7/10Timing: after-hours filing on Aug 4, 2026

Background

The filing is Chemours’ SEC Form 8-K reporting Q2 2026 results of operations and financial condition, with segment detail for TSS and Titanium Technologies and commentary on pricing actions and litigation progress.

Company-level read

Ticker impact

$CCNeutralMedium confidence
Context

Chemours reported Q2 2026 results, including net loss of $274M, adjusted EBITDA of $247M, and free cash flow up 128% YoY.

Expected impact

Likely modest, two-sided reaction depending on how investors weigh improved free cash flow and leverage versus continued net losses and litigation-related reserve impacts.

Evidence & confidence

This is a primary earnings release with multiple quantified items: FCF conversion 46%, net leverage down to 4.4x, and segment volume/pricing drivers, but it does not include explicit forward guidance in the provided text.

Market effects

Updates demand and pricing dynamics in TiO2 and refrigerants, which can influence sentiment across specialty chemicals and industrial materials pricing power.

Limited direct regional read-through; primarily US-listed company fundamentals.

Global pricing actions (TiO2) and refrigerant aftermarket volumes can affect broader industrial chemical supply-demand expectations.

Counterpoint

Improved free cash flow may be partly offset by litigation reserve timing and one-off tax impacts, so cash strength may not fully translate into sustainable earnings power.

Key entities

  • The Chemours Company

    NYSE-listed specialty chemicals producer reporting Q2 2026 financial results and cash/leverage progress.

  • Denise Dignam

    CEO quoted on disciplined execution, pricing actions, APM momentum, and balance sheet progress.

  • U.S. AIM Act

    Stationary technology AC transition referenced as a driver of elevated aftermarket demand in Q2 2025.

  • EPA and WVDEP

    Referenced in connection with legal and environmental reserves related to an announced settlement.

Related articles

$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after its Q2 earnings. The company reported slight revenue decline and adjusted EPS of $0.42, down 31% year over year, meeting expectations. Management cited lower Optane refrigerant sales due to supply-chain inventory and the wind-down of the SPS Capstone business. Full-year growth guidance remains 1% to 5%.

$CCMed

Why Chemours Plunged on Wednesday

Chemours (NYSE: CC) shares fell 18.7% after the company reported Q2 results. Revenue edged down and adjusted EPS fell 31% to $0.42, missing expectations. Lower Optane refrigerant sales and the prior wind-down of the SPS Capstone business weighed on results. Chemours still forecasts full-year growth of 1% to 5%.

$CCMedAI 8/10

The Chemours Company Reports Second Quarter Results

Chemours (NYSE: CC) reported Q2 2026 results: net sales about $1.6B, roughly flat year over year. Net loss attributable to Chemours was $274M ($1.81 per diluted share) versus $380M ($2.53) a year earlier. Adjusted net income was $64M ($0.42) and adjusted EBITDA $247M. Free cash flow rose 128% and net leverage fell to 4.4x. Chemours cited TiO2 pricing actions and APM Performance Solutions growth.

$MMMHighAI 9/10

New York sues 3M, DuPont and other chemical companies over PFAS pollution By Investing.com

New York Attorney General Letitia James sued 3M, DuPont, Chemours, Corteva and EIDP over alleged PFAS (“forever chemicals”) contamination. The complaint says the firms knew since decades-old research that PFAS were toxic but concealed risks, continued selling PFAS products, and allegedly misled consumers. New York seeks cleanup funding, consumer warnings, advertising changes, and damages and penalties.

$CCMedAI 8/10

Chemours OKs $450M deal with feds, DEP over PFAS pollution | Energy and Environment

The U.S. Department of Justice said Chemours agreed to a $450 million settlement with federal and state authorities over alleged PFAS violations at facilities in West Virginia, North Carolina and New Jersey. The DOJ cited breaches of the Clean Water Act, Toxic Substances Control Act and Resource Conservation and Recovery Act, including a $22.5 million civil penalty and a $90 million PFAS reduction program, plus about $60 million in controls and $280 million for drinking water. The deal is propos